The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Neuroendocrine tumor podcast explores neuroendocrine tumors (NETS), featuring world-renowned NET specialists and patients living with neuroendocrine cancer.
FDA approves Gallium-68 DOTATOC PET/CT, another new imaging agent, for use in scanning neuroendocrine tumors. Data showed Gallium-68 DOTATOC superior to decades-old methods for disease staging, treatment planning, and identifying unknown primary sites.
Life’s work of artist whose career was cut short by NET The Heritage of Sherborn, MA, will host a Retrospective Art Show and final sale
Coping with the uncertainty of a cancer diagnosis means finding ways to take your mind off cancer, to do what you enjoy most, finding meaning and purpose.
Neuroendocrine cancer patients traveling for pleasure, business, or cancer treatment, may need to consider a few extra details to ensure travel goes smoothly. These travel
UCSF Shares Promising Results of a Clinical Trial At the 2019 meeting of the American Cancer Society of Clinical Oncologists (ASCO), Emily Bergsland, MD, University
The need for tumor tissue in NETs The Neuroendocrine Tumor Research Foundation is on a mission to fill the urgent need for more neuroendocrine tumor
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
High School Student Finds Creative Way to Raise Money for NET Research Lilly is midway through twelth grade. Being a senior is typically the highlight
If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them?